Innovative technologies in Nanomedicines: from passive targeting to active targeting/from controlled pharmacokinetics to controlled intracellular pharmacokinetics.
Innovative technologies in Nanomedicines: from passive targeting to active targeting/from controlled pharmacokinetics to controlled intracellular pharmacokinetics.
复制标题
纳米医学创新技术：从被动靶向到主动靶向/从受控药代动力学到受控细胞内药代动力学。
DOI：
10.1002/mabi.201600179
复制
发表时间：
2017
影响因子：
4.6
通讯作者：
Harashima H.
中科院分区：
文献类型：
--
作者：
Sato Y;Sakurai Y;Kajimoto K;Nakamura T;Yamada Y;Akita H;Harashima H.
Nanomedicines promise to extend drug therapy from small molecular compounds to proteins/nucleic acids/genes. Multifunctional envelope‐type nanodevices (MENDs) have been developed for delivering such molecules to the site of action. The YSK‐MEND contains new types of pH‐responsive cationic lipids to efficiently deliver siRNA to hepatocytes via receptor‐mediated endocytosis and use in treating hepatitis C and B in model mice. The RGD ligand is introduced to target tumor endothelial cells (TEC) and RGD‐MEND is able to send siRNA to TEC to regulate the function of tumor microenvironments. The MITO‐Porter is also developed to target mitochondria via membrane fusion. Antisense oligo RNA in the MITO‐Porter permits the knock down of mitochondrial function. Finally, the ssPalms is designed based on a new concept of pH‐dependent protonation in endosomes and cleavage of SS bonds in the reducing conditions in cytosol. These new technologies promise to stimulate the use of Nanomedicines in the future.
